2015 Antineoplastics

I and II. STIs that target Bcr-Abl and EGFR

Mechanisms of action

DASATANIB, IMATINIB (Gleevec), NILOTINIB

ERLOTINIB (Tarceva/Genetech), GEFITINIB (Iressa/AstraZeneca)

LAPATINIB

Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 11-apr-15 9:39 AM